50 related articles for article (PubMed ID: 36144398)
1. Feasibility Study of Developing a Saline-Based Antiviral Nanoformulation Containing Lipid-Soluble EGCG: A Potential Nasal Drug to Treat Long COVID.
Frank N; Dickinson D; Garcia W; Liu Y; Yu H; Cai J; Patel S; Yao B; Jiang X; Hsu S
Viruses; 2024 Jan; 16(2):. PubMed ID: 38399972
[TBL] [Abstract][Full Text] [Related]
2. Dual regulations on texture and water mobility of shrimp surimi gel with sustained-release epigallocatechin-3-gallate in γ-cyclodextrin metal organic frameworks: Insights into functionality and mechanisms.
Wang Z; Li D; Liu X; Zhang M; Zhu B; Liu D; Zhou D
Food Res Int; 2023 Dec; 174(Pt 1):113522. PubMed ID: 37986425
[TBL] [Abstract][Full Text] [Related]
3. Encapsulation Alleviates the Auto-browning of Epigallocatechin-3-gallate in Aqueous Solutions through Regulating Molecular Self-Aggregation Behavior.
Wang Z; Yin F; Li D; Wang X; Guo C; Liu D; Zhu B; Zhou D
J Agric Food Chem; 2023 Oct; 71(40):14720-14730. PubMed ID: 37756148
[TBL] [Abstract][Full Text] [Related]
4. Potentialities of Tannase-Treated Green Tea Extract in Nutraceutical and Therapeutic Applications.
Ong CB; Annuar MSM
Appl Biochem Biotechnol; 2024 May; ():. PubMed ID: 38713339
[TBL] [Abstract][Full Text] [Related]
5. Pre-Clinical Evaluation of the Antiviral Activity of Epigalocatechin-3-Gallate, a Component of Green Tea, against Influenza A(H1N1)pdm Viruses.
Stannard H; Koszalka P; Deshpande N; Desjardins Y; Baz M
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140688
[TBL] [Abstract][Full Text] [Related]
6. New Advances in Viral and Microorganism Disinfectants.
Onodera T; Kirisawa R
Microorganisms; 2023 Oct; 11(10):. PubMed ID: 37894187
[TBL] [Abstract][Full Text] [Related]
7. Cyclodextrins for the Delivery of Bioactive Compounds from Natural Sources: Medicinal, Food and Cosmetics Applications.
Christaki S; Spanidi E; Panagiotidou E; Athanasopoulou S; Kyriakoudi A; Mourtzinos I; Gardikis K
Pharmaceuticals (Basel); 2023 Sep; 16(9):. PubMed ID: 37765082
[TBL] [Abstract][Full Text] [Related]
8. Anti-influenza Virus Effects of Catechins: A Molecular and Clinical Review.
Ide K; Kawasaki Y; Kawakami K; Yamada H
Curr Med Chem; 2016; 23(42):4773-4783. PubMed ID: 27881069
[TBL] [Abstract][Full Text] [Related]
9. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea.
Steinmann J; Buer J; Pietschmann T; Steinmann E
Br J Pharmacol; 2013 Mar; 168(5):1059-73. PubMed ID: 23072320
[TBL] [Abstract][Full Text] [Related]
10. Epigallocatechin Gallate Stabilized by Cyclodextrin Inactivates Influenza Virus and Human Coronavirus 229E.
Matsuura R; Kawamura A; Matsumoto Y; Iida Y; Kanayama M; Kurokawa M; Aida Y
Microorganisms; 2022 Sep; 10(9):. PubMed ID: 36144398
[TBL] [Abstract][Full Text] [Related]
11. Antiviral effect of catechins in green tea on influenza virus.
Song JM; Lee KH; Seong BL
Antiviral Res; 2005 Nov; 68(2):66-74. PubMed ID: 16137775
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the infectivity of influenza virus by tea polyphenols.
Nakayama M; Suzuki K; Toda M; Okubo S; Hara Y; Shimamura T
Antiviral Res; 1993 Aug; 21(4):289-99. PubMed ID: 8215301
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of influenza virus-induced reactive oxygen species formation by epigallocatechin gallate derived from green tea.
Ling JX; Wei F; Li N; Li JL; Chen LJ; Liu YY; Luo F; Xiong HR; Hou W; Yang ZQ
Acta Pharmacol Sin; 2012 Dec; 33(12):1533-41. PubMed ID: 22941291
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of influenza virus internalization by (-)-epigallocatechin-3-gallate.
Kim M; Kim SY; Lee HW; Shin JS; Kim P; Jung YS; Jeong HS; Hyun JK; Lee CK
Antiviral Res; 2013 Nov; 100(2):460-72. PubMed ID: 23954192
[TBL] [Abstract][Full Text] [Related]
15. Epigallocatechin-3-gallate exhibits antiviral effects against the duck Tembusu virus via blocking virus entry and upregulating type I interferons.
Zhu Y; Gu X; Zhang M; Lv X; Zhang C; Li J; Hu Z; Wu Q; Zhang R; Wei J; Huang R; Wang B; Wang Q; Wang G
Poult Sci; 2021 Apr; 100(4):100989. PubMed ID: 33647721
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
